IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice

Journal of Immunology

Volumn 167, Issue 10, 2001, Pages 5913-5920

  Faggioni, R ^a   Cattley, R C ^a   Guo, J ^a   Flores, S ^a   Brown, H ^a   Qi, M ^a   Yin, S ^a   Hill, D ^a   Scully, S ^a   Chen, C ^a   Brankow, D ^a   Lewis, J ^a   Baikalov, C ^a   Yamane, H ^a   Meng, T ^a   Martin, F ^a   Hu, S ^a   Boone, T ^a   Senaldi, G ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CONCANAMYCIN A; FAS ANTIBODY; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 18; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; PSEUDOMONAS EXOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GRANULOMA; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LIVER DISEASE; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIACEAE; PROTEIN EXPRESSION; SENSITIZATION;

EID: 0035889930     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.10.5913     Document Type: Article

References (51)

1. IL-18: A Th1-inducing, proinflammatory cytokine and new member of the IL-1 family
2. Cloning of a new cytokine that induces IFN-γ production by T cells
3. erk-21
4. IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-γ
5. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-γ production
6. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively
7. + human blood mononuclear cells
8. Interleukin-18 induces production of proinflammatory cytokines in mice: No intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1β
9. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
10. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia
11. An IFN-γ-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis
12. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response
13. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18
14. Targeting interleukin 18 with interleukin 18 binding protein
15. Soluble cytokine receptors: Their roles in immunoregulation, disease, and therapy
16. Cytokine receptors encoded by poxviruses: A lesson in cytokine biology
17. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response
18. IL-18 binding and inhibition of interferon γ induction by human poxvirus-encoded proteins
19. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment
20. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
21. Two tumor necrosis factor-binding proteins purified from human urine: Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors
22. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
23. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
24. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production
25. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme
26. Defective NK cell activity and Th1 response in IL-18-deficient mice
27. IL-18 accounts for both TNF-α- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice
28. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: Role of tumor necrosis factor α and IL-18
29. Caspase-1-independent, Fas-Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice
30. Contribution of Fas ligand to T cell-mediated hepatic injury in mice
31. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF
32. Pathophysiological roles of interleukin-18 in inflammatory liver diseases
33. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis
34. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure
35. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
36. Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-γ-deficient mice by a concomitant reduction of TNF-α, IL-12, and IL-18 production
37. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones
38. Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease
39. ExperimentaI hepatitis and role of cytokines
40. Interleukin-18 regulation of interferon γ production and cell proliferation as shown in interleukin-1β-converting enzyme (caspase-1)-deficient mice
41. Lethal effect of the anti-Fas antibody in mice
42. Serum interferon-γ-inducing factor/IL-18 levels in primary biliary cirrhosis
43. Interleukin 18 (IL-18) levels in patients with sepsis
44. Elevation of IL-18 in human sepsis
45. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection
46. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells
47. A proinflammatory role for IL-18 in rheumatoid arthritis
48. Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis
49. Interteukin-18, rheumatoid arthritis, and tissue destruction
50. Interleukin 18: A pleiotropic participant in chronic inflammation
51. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist